NewsRx

Search our medical news database

Finance

MSA developer announces commercialization and funding objectives

Published in Women's Health Weekly, July 24th, 2003

Genesis Bioventures, Inc., (GBI) announced the near-term objectives for the company in its drive to commercialize the Mammastatin Serum Assay (MSA) risk assessment tool for breast cancer.

GBI recently completed a direct licensing agreement with the University of Michigan for the mammastatin technology from which the MSA is derived. The increased control over this technology now affords to GBI the opportunity, subject to adequate financing, to put the development process on a fast track commercialization strategy.

GBI is required to complete certain additional financings in order to complete that anticipated schedule. The company is working to...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook